Novo Nordisk's Oral Semaglutide Shows Promise for Weight Loss
TL;DR Summary
A clinical trial shows that an oral form of semaglutide, a drug used for weight loss and diabetes management, is effective in significantly reducing body weight, offering a less invasive alternative to injections. The study involved 205 participants and found an average weight loss of 13.6%, with manageable side effects, paving the way for potential regulatory approval of oral Ozempic.
- Ozempic in a Pill? Clinical Trial Finds Oral Semaglutide Works For Weight Loss ScienceAlert
- Wegovy pill could deliver as much weight loss as the shot, trial shows The Washington Post
- Why Shares in Novo Nordisk Soared This Week Yahoo Finance
- Novo Nordisk shares climb after positive anti-obesity pill results The Guardian
- Novo Nordisk pads case for Wegovy in a pill as oral obesity asset nears FDA decision Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 3 min read
Condensed
90%
580 → 60 words
Want the full story? Read the original article
Read on ScienceAlert